{"id":"mmx-mesalamine","safety":{"commonSideEffects":[{"rate":"5-10%","effect":"Headache"},{"rate":"5-10%","effect":"Abdominal pain"},{"rate":"5-10%","effect":"Diarrhea"},{"rate":"3-8%","effect":"Nausea"},{"rate":"3-8%","effect":"Flatulence"}]},"_chembl":{"chemblId":"CHEMBL704","moleculeType":"Small molecule","molecularWeight":"153.14"},"_fixedAt":"2026-03-30T18:00:24.760462","_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Mesalamine (5-aminosalicylic acid) is a topical anti-inflammatory agent that works by inhibiting prostaglandin and leukotriene production in the colon. The MMX formulation uses a multi-matrix system to delay drug release until it reaches the colon, maximizing local therapeutic effect while minimizing systemic exposure and side effects.","oneSentence":"MMX Mesalamine is a delayed-release formulation of mesalamine that delivers the anti-inflammatory drug to the colon to reduce inflammation in inflammatory bowel disease.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:55:35.782Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Induction of remission of mild to moderate ulcerative colitis"},{"name":"Maintenance of remission of ulcerative colitis"}]},"_fixedFields":["pubmed(31)"],"trialDetails":[{"nctId":"NCT01469637","phase":"PHASE1","title":"Sulfamethoxazole Drug Interaction Study With MMX® Mesalazine/Mesalamine","status":"COMPLETED","sponsor":"Shire","startDate":"2011-11-07","conditions":"Healthy","enrollment":44},{"nctId":"NCT01130844","phase":"PHASE1","title":"Safety and Pharmacokinetics of MMX Mesalamine in Children and Adolescents With Ulcerative Colitis","status":"COMPLETED","sponsor":"Shire","startDate":"2010-10-08","conditions":"Ulcerative Colitis","enrollment":52},{"nctId":"NCT00545740","phase":"PHASE3","title":"Prevention of Recurrence of Diverticulitis","status":"COMPLETED","sponsor":"Shire","startDate":"2007-11-28","conditions":"Diverticulitis","enrollment":590},{"nctId":"NCT00151892","phase":"PHASE3","title":"Efficacy and Safety of SPD476 in Maintaining Remission in Patients With Ulcerative Colitis","status":"COMPLETED","sponsor":"Shire","startDate":"2005-04-08","conditions":"Ulcerative Colitis","enrollment":829},{"nctId":"NCT00446849","phase":"PHASE4","title":"Strategies in Maintenance for Patients Receiving Long-term Therapy (S.I.M.P.L.E.) With MMX (Multi-Matrix System) Mesalamine for Ulcerative Colitis (UC)","status":"COMPLETED","sponsor":"Shire","startDate":"2007-05-01","conditions":"Ulcerative Colitis","enrollment":290},{"nctId":"NCT00545103","phase":"PHASE3","title":"Prevention of Recurrence of Diverticulitis","status":"COMPLETED","sponsor":"Shire","startDate":"2007-12-06","conditions":"Diverticulitis","enrollment":592},{"nctId":"NCT01418365","phase":"PHASE1","title":"Metronidazole Drug Interaction Study With MMX® Mesalazine/Mesalamine","status":"COMPLETED","sponsor":"Shire","startDate":"2011-08-22","conditions":"Healthy","enrollment":30},{"nctId":"NCT01402947","phase":"PHASE1","title":"Ciprofloxacin XR Drug Interaction Study With MMX® Mesalazine/Mesalamine","status":"COMPLETED","sponsor":"Shire","startDate":"2011-07-25","conditions":"Healthy","enrollment":30},{"nctId":"NCT01124149","phase":"PHASE4","title":"Ability to Maintain or Achieve Clinical and Endoscopic Remission With MMX Mesalamine Once Daily in Adults With Ulcerative Colitis","status":"COMPLETED","sponsor":"Shire","startDate":"2010-06-29","conditions":"Ulcerative Colitis","enrollment":759},{"nctId":"NCT02093663","phase":"PHASE3","title":"Safety and Efficacy of MMX Mesalamine/Mesalazine in Pediatric Subjects With Mild to Moderate Ulcerative Colitis","status":"COMPLETED","sponsor":"Shire","startDate":"2014-12-12","conditions":"Ulcerative Colitis","enrollment":107},{"nctId":"NCT01442688","phase":"PHASE1","title":"Amoxicillin Drug Interaction Study With MMX® Mesalazine/Mesalamine","status":"COMPLETED","sponsor":"Shire","startDate":"2011-10-07","conditions":"Healthy","enrollment":62},{"nctId":"NCT00679432","phase":"PHASE3","title":"(CB-01-02/01) Randomized Placebo Controlled Trial of Budesonide-multi-matrix System (MMX™) 6 mg and 9 mg in Patients With Ulcerative Colitis","status":"COMPLETED","sponsor":"Bausch Health Americas, Inc.","startDate":"2008-06","conditions":"Ulcerative Colitis","enrollment":510},{"nctId":"NCT01532648","phase":"PHASE3","title":"Randomized Placebo-Controlled Trial of Budesonide Multi-Matrix System (MMX®) 9 Milligrams (mg) in Participants With Ulcerative Colitis Currently on a 5-Aminosalicylic Acid (5-ASA)","status":"COMPLETED","sponsor":"Bausch Health Americas, Inc.","startDate":"2012-01-27","conditions":"Ulcerative Colitis","enrollment":510},{"nctId":"NCT00867438","phase":"PHASE2","title":"Efficacy and Tolerability of a New Oral Extended-Release Formulation Containing Parnaparin Sodium, Administered Add-on Therapy","status":"COMPLETED","sponsor":"Cosmo Technologies Ltd","startDate":"2007-01","conditions":"Ulcerative Colitis","enrollment":133}],"_emaApprovals":[],"_faersSignals":[{"count":1,"reaction":"ECZEMA"},{"count":1,"reaction":"PALMAR-PLANTAR ERYTHRODYSAESTHESIA SYNDROME"}],"_approvalHistory":[],"publicationCount":31,"recentPublications":[{"date":"2026 Jan-Dec","pmid":"41541898","title":"Real-World Adherence and Relapse Risk in Mesalamine Treatment for Ulcerative Colitis: Insights from a Large Japanese Medical Claims Database.","journal":"Inflammatory intestinal diseases"},{"date":"2024 Sep","pmid":"38797598","title":"MMX mesalamine: A modern twist on a classic treatment.","journal":"Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver"},{"date":"2024 Sep","pmid":"38705783","title":"MMX mesalamine in ulcerative colitis: Major advantages towards classical mesalamine formulations.","journal":"Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver"},{"date":"2022 Feb 11","pmid":"35208599","title":"A Case of Stevens-Johnson Syndrome Complicated with Multimatrix System Mesalamine in Ulcerative Colitis.","journal":"Medicina (Kaunas, Lithuania)"},{"date":"2020 Aug 12","pmid":"32786164","title":"Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis.","journal":"The Cochrane database of systematic reviews"}],"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Lialda, SPD476","Lialda"],"phase":"marketed","status":"active","brandName":"MMX Mesalamine","genericName":"MMX Mesalamine","companyName":"Shire","companyId":"shire","modality":"Small molecule","firstApprovalDate":"","aiSummary":"MMX Mesalamine is a small molecule that inhibits arachidonate 5-lipoxygenase, an enzyme involved in the inflammatory process. It is used to prevent the recurrence of diverticulitis and has been studied in clinical trials for the treatment of ulcerative colitis and as a healthy control.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":2},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}